+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 47 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.

Age: 18Years +All GendersPhase 3
206 locations
R

Actively Recruiting

Researchers are evaluating zanidatamab combined with chemotherapy for people with early-stage HER2-positive breast cancer. This Phase 2 trial aims to determine if this combination is safe and effective compared to standard treatments. Participants have newly diagnosed Stage II or III invasive breast cancer confirmed to be HER2-positive, with specific health and organ function requirements. Participants are randomly assigned to one of three groups zanidatamab with paclitaxel, zanidatamab with docetaxel and carboplatin, or trastuzumab and pertuzumab with docetaxel and carboplatin. All drugs are given intravenously before surgery. After completing the neoadjuvant therapy, participants will have a mastectomy or breast conserving surgery as decided by their doctor. During the study, participants will have regular assessments including heart function tests, adverse event monitoring, and evaluations of tumor response up to 8 months. Additional follow-up for safety and survival outcomes extends up to nearly 4 years. Researchers will measure the number of participants achieving complete tumor response, side effects, and long-term survival, while monitoring drug levels and immune reactions.

Age: 18Years +All GendersPhase 2
53 locations
C

Actively Recruiting

Researchers are evaluating how well a new injectable medicine called cagrilintide helps adults with excess body weight to lose weight. This phase 3 trial compares two different presentations of cagrilintide to placebo in people with overweight or obesity. The purpose is to understand the relative change in body weight from the start of treatment to the end of 26 weeks of treatment. Participants will be randomly assigned to one of three groups receiving weekly subcutaneous injections for 26 weeks one group receives cagrilintide with placebo matched to semaglutide in one device and placebo matched to cagrilintide in another another group receives cagrilintide in one device with matched placebos in the other and the last group receives matched placebos in both devices. This double-blind study uses devices for administration and treatment allocation is random. During the study, participants will have regular assessments including measurements of body weight and monitoring for adverse events from the start through 33 weeks. The main outcome measured is the relative change in body weight after 26 weeks of treatment. Safety is also monitored by counting any treatment-emergent adverse events or serious adverse events. Participants are involved for about 9 months in total.

Age: 18Years +All GendersPhase 3
36 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
G

Actively Recruiting

Researchers are evaluating the safety and clinical activity of EIK1001, a drug that targets Toll like receptor 78, given intravenously with pembrolizumab and chemotherapy in patients with stage 4 non-small cell lung cancer NSCLC. This global, multicenter, double-blind, placebo-controlled study involves participants who have not received prior systemic therapy and aims to assess treatment effects in both squamous and non-squamous NSCLC types. The trial is conducted in two phases Phase 2 and Phase 3 and includes dose optimization, dose expansion, and confirmatory hypothesis testing. Participants are randomly assigned to one of three groups EIK1001 at one of two selected doses plus standard chemotherapy and pembrolizumab, or placebo plus standard chemotherapy and pembrolizumab. Chemotherapy regimens differ based on tumor histology, with pemetrexed plus carboplatin or cisplatin for non-squamous NSCLC, and carboplatin plus paclitaxel or nab-paclitaxel for squamous NSCLC. Treatments are administered intravenously, and the study is designed to evaluate safety and efficacy over time. During the study, participants undergo regular assessments to monitor progression-free survival, overall survival, and objective response, which are tracked for up to 6 to 10 years depending on the measure. Additional evaluations include adverse event incidence and duration of response. Participants are monitored closely with clinical visits throughout the study period, which may last several years, to ensure safety and collect data on treatment effects.

Age: 18Years +All GendersPhase 2Phase 3
42 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of the FDA-approved VARIPULSE catheter system for pulmonary vein isolation PVI in treating people with symptomatic paroxysmal atrial fibrillation PAF. This study focuses on participants who are candidates for catheter ablation due to symptoms and have not responded well to certain antiarrhythmic drugs. Participants will undergo electrophysiology mapping and pulsed field ablation PFA using the VARIPULSE catheter combined with the TRUPULSE generator. This treatment is designed to isolate pulmonary veins to manage atrial fibrillation symptoms. The study observes outcomes both shortly after the procedure and over the long term. During the study, participants will be monitored for early adverse events within 7 days after the ablation procedure. They will also be followed for freedom from documented atrial tachyarrhythmia episodes from about 2 months up to 3 years after treatment. Assessments include clinical evaluations and adherence to follow-up testing to understand the devices safety and effectiveness over time.

Age: 22Years +All GendersPhase Not Applicable
25 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate targeting EGFR and HER3 with a chemotherapy payload, compared to treatment chosen by physicians including paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine for patients with first-line metastatic triple-negative breast cancer TNBC or low estrogen receptor ER-low, HER2-negative breast cancer who cannot receive anti-PDL1 or endocrine therapies. This study includes adults with locally advanced, recurrent inoperable, or metastatic disease who meet specific eligibility criteria. Participants are randomly assigned to receive iza-bren or one of the physicians choice chemotherapy regimens. The treatments are given at specified doses on scheduled days. The study includes two phases Phase 2 to determine the recommended dose of iza-bren and Phase 3 to compare progression-free survival and other outcomes. The study will last several years, with follow-up extending up to approximately 47 months after randomization. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, laboratory tests, and monitoring for adverse events. Quality of life questionnaires will also be completed. Researchers will track progression-free survival, overall survival, treatment-related side effects, tumor size changes, and patient-reported outcomes to evaluate the treatments. The total participation duration may extend up to several years depending on treatment response and follow-up requirements.

Age: 18Years +All GendersPhase 2Phase 3
295 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, and changes in disease activity of an investigational drug called ABBV-706 compared to standard treatments for relapsed or refractory small cell lung cancer SCLC, a fast-growing cancer that often spreads early to other parts of the body. This Phase 3 trial involves about 531 adult participants worldwide and aims to assess how ABBV-706 works against current standard care options including topotecan, lurbinectedin, or amrubicin. Participants with SCLC will be randomly assigned to receive either ABBV-706 or one of the standard care treatments. ABBV-706 and the comparator drugs are given through intravenous infusion, with topotecan also available orally. The entire study is expected to last approximately 53 months, during which participants will receive their assigned treatment as part of this extended timeframe. During the study, participants will attend regular visits at a hospital or clinic for medical assessments, which include blood tests, scans, and questionnaires to monitor disease progression and treatment effects. Researchers will measure outcomes such as overall response rate, overall survival, progression-free survival, and quality of life changes. Safety and adverse events will be tracked throughout the study duration of up to 53 months.

Age: 18Years +All GendersPhase 3
72 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of standard chemotherapy combined with bevacizumab, with or without the addition of INCA33890, for the first-line treatment of adults with metastatic microsatellite stable colorectal cancer who have not received prior systemic treatment for metastatic disease. This phase 3 randomized, double-blind study aims to compare these treatment approaches to better understand their impact on disease progression. Participants will receive either INCA33890 or a placebo in combination with bevacizumab and FOLFOX chemotherapy at doses defined by the study protocol. The treatments are given as part of a randomized, parallel group design where neither the participants nor the investigators know which treatment is assigned. This study will assess outcomes over several years, with primary evaluation focused on progression-free survival for up to 3 years. Throughout the study, participants will be monitored regularly for treatment response, survival, and safety through various assessments including laboratory tests and quality of life questionnaires. Researchers will measure overall survival, objective response rate, duration of response, and treatment-related adverse events for up to 4 years. Quality of life changes will also be tracked using validated questionnaires. The total duration of participation may extend up to around 4 years, with ongoing safety and efficacy evaluations.

Age: 18Years +All GendersPhase 3
297 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.

Age: 18Years +All GendersPhase 3
283 locations

1-10 of 47

1